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With more involvement and increased responsibility
of healthcare professionals, the patients themselves,
researchers, pharmaceutical industry, regulatory
authorities and international organizations, safety of
the treatment significantly would be improved and
would reduce health care costs.
The system of pharmacovigilance has an international character. The
international cooperation center for monitoring of medications (The
Uppsala Monitoring Centre - UMC) which is under WHO Headquarter
guidance, is a network of eighty National Centers that are collecting and
reporting suspected adverse reactions to drugs (ADRs). It is the largest
database of ADRs reports in the world, and it is main source for
generating signals of previously unknown ADRs, also studying the issues
of medication safety. Regulation in the Republic of Macedonia are fully
harmonized with the recommendations of the WHO and the EU,
however, the reports for adverse reactions to the National Center are
significantly less than the other European countries.
Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and
prevention of adverse effects or any other drug-related problem. WHO established its Programme for International Drug
Monitoring in response to the thalidomide disaster detected in 1961. Together with the WHO Collaborating Centre for
International Drug Monitoring, Uppsala, WHO promotes PV at the country level. At the end of 2010, 134 countries were part
of the WHO PV Programme. The aims of PV are to enhance patient care and patient safety in relation to the use of
medicines; and to support public health programmes by providing reliable, balanced information for the effective assessment
of the risk-benefit profile of medicines.
- The purpose of this work is to present the significance and
development of pharmacovigilance as part of the
pharmaceutical and healthcare work, the centers and
participants in the system of pharmacovigilance, side
effects of the drugs and the correct manner of their
reporting, and post-marketing monitoring of drugs.
MATERIALS AND METHODS
- Primary, secondary and tertiary literature
- Guidelines and recommendations according to WHO, EMA and
FDA
- Data from Register of medicines of Republic of Macedonia
- Evaluation of documents from centers for monitoring adverse drug
reactions and the written regulations of Republic of Macedonia.
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